Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies (Globe Newswire)

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical stage pharmaceutical development company, announced that it has signed an agreement with Charles River Laboratories, an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries, for preclinical studies of AP-188 (N,N-Dimethyltryptamine or DMT) for the company’s stroke clinical research program. Algernon’s preclinical study of DMT will be conducted at the Charles River research facility in Finland.

Learn more about Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies.
X